open access

Vol 10, No 3 (2021)
Case report
Published online: 2021-03-05
Get Citation

Hydroxychloroquine used to treat diabetic hand syndrome: a case report

Saibal Chakravorty, Aditya Chakravorty
DOI: 10.5603/DK.a2021.0027
·
Clinical Diabetology 2021;10(3):307-309.

open access

Vol 10, No 3 (2021)
Case reports
Published online: 2021-03-05

Abstract

Increased incidence of musculoskeletal disorders has
been linked with diabetes mellitus (DM). Focus of antidiabetic
therapy is prominently towards controlling
blood glucose levels along with prevention and management
of micro- and macrovascular complications.
These complaints often receive less attention and are
undertreated. No specific drug treatment has been
recommended for the management of musculoskeletal
complications of DM. Hydroxychloroquine (HCQ) decreases
joint inflammation and pain in rheumatoid arthritis
(RA). In India, due to its proven antidiabetic effect,
it is officially approved for the management of type 2
diabetes mellitus (T2DM). Due to its anti-inflammatory
and antidiabetic effect, it may alter the clinical course
of musculoskeletal complications in T2DM patients.
We report a case of 55-year-old male patient, diagnosed
with T2DM since last 6 years. The patient
had bilateral musculoskeletal involvement of upper
extremities at the time of presentation. He had difficulty
in moving smaller joints of hand, closing of
fist and trigger finger, all suggestive of diabetic hand
syndrome. Good improvement in joint mobility was
observed after initiation of HCQ 400 mg once daily as
add-on to existing antidiabetic regimen.
HCQ was found to be effective in relieving symptoms
of musculoskeletal complications as well as controlling
blood glucose level in our patient. More clinical studies
investigating use of HCQ in diabetic musculoskeletal
complications are warranted.

Abstract

Increased incidence of musculoskeletal disorders has
been linked with diabetes mellitus (DM). Focus of antidiabetic
therapy is prominently towards controlling
blood glucose levels along with prevention and management
of micro- and macrovascular complications.
These complaints often receive less attention and are
undertreated. No specific drug treatment has been
recommended for the management of musculoskeletal
complications of DM. Hydroxychloroquine (HCQ) decreases
joint inflammation and pain in rheumatoid arthritis
(RA). In India, due to its proven antidiabetic effect,
it is officially approved for the management of type 2
diabetes mellitus (T2DM). Due to its anti-inflammatory
and antidiabetic effect, it may alter the clinical course
of musculoskeletal complications in T2DM patients.
We report a case of 55-year-old male patient, diagnosed
with T2DM since last 6 years. The patient
had bilateral musculoskeletal involvement of upper
extremities at the time of presentation. He had difficulty
in moving smaller joints of hand, closing of
fist and trigger finger, all suggestive of diabetic hand
syndrome. Good improvement in joint mobility was
observed after initiation of HCQ 400 mg once daily as
add-on to existing antidiabetic regimen.
HCQ was found to be effective in relieving symptoms
of musculoskeletal complications as well as controlling
blood glucose level in our patient. More clinical studies
investigating use of HCQ in diabetic musculoskeletal
complications are warranted.

Get Citation

Keywords

type 2 diabetes mellitus, complications, musculoskeletal, hand syndrome, hydroxychloroquine

About this article
Title

Hydroxychloroquine used to treat diabetic hand syndrome: a case report

Journal

Clinical Diabetology

Issue

Vol 10, No 3 (2021)

Article type

Case report

Pages

307-309

Published online

2021-03-05

DOI

10.5603/DK.a2021.0027

Bibliographic record

Clinical Diabetology 2021;10(3):307-309.

Keywords

type 2 diabetes mellitus
complications
musculoskeletal
hand syndrome
hydroxychloroquine

Authors

Saibal Chakravorty
Aditya Chakravorty

References (7)
  1. Mueller MJ. Musculoskeletal impairments are often unrecognized and underappreciated complications from diabetes. Phys Ther. 2016; 96(12): 1861–1864.
  2. Das AK, Kalra S, Tiwaskar M, et al. Expert group consensus opinion: role of anti-inflammatory agents in the management of type-2 diabetes (T2D). J Assoc Physicians India. 2019; 67(12): 65–74.
  3. Das SK, Pareek A, Mathur DS, et al. Efficacy and safety of hydroxychloroquine sulphate in rheumatoid arthritis: a randomized, double-blind, placebo controlled clinical trial--an Indian experience. Curr Med Res Opin. 2007; 23(9): 2227–2234.
  4. Wondafrash DZ, Desalegn TZ, Yimer EM, et al. Potential effect of hydroxychloroquine in diabetes mellitus: a systematic review on preclinical and clinical trial studies. J Diabetes Res. 2020; 2020: 5214751.
  5. Joshi S, Vadgama J, Panikar V, et al. Hydroxychloroquine in type 2 diabetes with adhesive capsulitis. Endocrine Practice. 2017; 23: 294.
  6. Majjad A, Errahali Y, Toufik H, et al. Musculoskeletal disorders in patients with diabetes mellitus: a cross-sectional study. Int J Rheumatol. 2018; 2018: 3839872.
  7. Khan K, Ali K, Farrukh S, et al. AB1152 Musculoskeletal manifestation of diabetes mellitus is highly prevalent and is associated with poor diabetic control. Other orphan diseases. 2018.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl